trending Market Intelligence /marketintelligence/en/news-insights/trending/iXB4h1qnM4_bPCL8o6uuTg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

AstraZeneca's Tagrisso fast-tracked for 1st-line treatment of lung cancer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AstraZeneca's Tagrisso fast-tracked for 1st-line treatment of lung cancer

AstraZeneca PLC's Tagrisso was granted breakthrough therapy designation by the U.S. Food and Drug Administration for first-line treatment of patients with a certain type of lung cancer.

The FDA granted the designation based on data from the phase 3 FLAURA trial of Tagrisso versus standard-of-care therapy in previously-untreated patients.

Tagrisso, or osimertinib, is currently approved in over 50 countries, including the U.S. and EU, as a second-line of treatment for patients with locally advanced or epidermal growth factor receptor-mutated nonsmall cell lung cancer.